PUBLISHER: DelveInsight | PRODUCT CODE: 1462294
PUBLISHER: DelveInsight | PRODUCT CODE: 1462294
"FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about FARXIGA for myocardial infarction in the seven major markets. A detailed picture of the FARXIGA for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FARXIGA for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FARXIGA market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
FARXIGA (known as FORXIGA outside the US) (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor. Research has shown FARXIGA's efficacy in preventing and delaying cardiorenal disease while protecting the organs - important findings given the underlying links between the heart, kidneys, and pancreas.
FARXIGA is approved in adults and children aged 10 and above for treating insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. FARXIGA is also approved for HFrEF and CKD treatment based on the findings of the DAPA-HF and DAPA-CKD Phase III trials.
FARXIGA is currently being tested in the DAPA-MI Phase III trial, a first-of-its-kind, registry-based randomized controlled trial in patients without type 2 diabetes following an acute MI or heart attack. The DAPA-MI trial is conducted in collaboration with Uppsala Clinical Research Center (UCR) and Myocardial Ischaemia National Audit Project (MINAP) in the UK.
As per the company's Q3 2022 report, data readouts from the Phase III (DAPA-MI) trial are anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
FARXIGA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of FARXIGA for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of FARXIGA for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.